Triple class exposed patients with multiple myeloma (MM) represent an unmet need with outcomes remaining poor with those with relapsed/refractory multiple myeloma (RRMM) having a mere 29.8% overall response rate and 12.4-month median overall survival. We explore emerging strategies focusing on bispecific antibodies and CAR-T cell therapies for treatment of refractory myeloma.
Margaret Locke, Amanda Lee, Maria J Nieto
